Full-Time

Client Service Specialist

Bio-Techne

Bio-Techne

1,001-5,000 employees

Purified proteins and reagents supplier

Compensation Overview

$49.7k - $81.7k/yr

Minneapolis, MN, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Salesforce
Data Analysis
Requirements
  • Requires a Bachelor’s Degree in related field or equivalent experience in a related field and up to 2 years of relevant experience
  • Advanced, functional knowledge about Bio-Techne Reagents and consumable products with emphasis on reagents to support CGT and Regenerative medicine workflows (antibodies, recombinant proteins, small molecules, immunoassays, and cell culture reagents) and their uses, competitor(s) and their product(s), and the marketplace, as well as the ability to develop in-depth knowledge about customer workflows.
  • A passion for the product(s) and company and a deep empathy for the customer and their needs, with the ability to combine and integrate various information into opportunities and strategies.
  • Proven ability to work collaboratively in a team selling environment.
  • Excellent interpersonal relationship skills, leadership, and decisiveness to solicit key ideas and information and obtain alignment, as well as the confidence to make decisions.
  • Ability to work independently to gain assistance from many in the organization in order to make the necessary decisions to drive projects and requirements.
  • Proficient in planning, organization, problem solving, and multi-tasking to carry out essential functions in a timely, efficient manner.
  • Outstanding oral and written communication and presentation skills allowing the ability to communicate professionally across all layers of the organization as well as customers’ and prospects’ organizations.
  • Proficient in the use of computer applications and software that allow for analysis and presentation of data as well as productivity (i.e. Microsoft Office, Salesforce.com), as well as ability to become proficient in proprietary databases and ERP solutions (Microsoft AX)
  • Ability to handle sensitive and proprietary information with discretion and confidentiality.
  • Skills in problem solving and critical thinking, including the ability to identify and appropriately evaluate an alternative course of action.
Responsibilities
  • Work in team to support and meet assigned territory goals.
  • Proactively plan and anticipate customer needs and requirements by collecting and reviewing forecasts to ensure set expectations and goals are consistently met. Take ownership of requests and follow through with requests to completion by collaborating with Field Sales, Customer Service, Technical Service, Product Management, Operations, etc. when appropriate.
  • Lead operational alignment calls with Key Accounts. Participate in joint steering team meetings, business reviews, and other customer-facing activities.
  • Prepare sales quotes for bulk, GMP, Cell and Gene Therapy reagents, custom orders and other high-value and high-need business opportunities as assigned.
  • Contribute to the maintenance of lasting relationships with customers through knowledgeable communication and proactive resolution of questions or issues. Work in partnership with regional sales teams across all Bio-Techne divisions to deliver superior service.
  • Manage all aspects of order cycle as necessary to ensure customer satisfaction.
  • Effectively manage work situations of high degree of complexity, which could impact company image and/or sales dollars and costs.
  • Triage inbound key-customer inquiries and respond or route such requests in an efficient manner.
  • Document communications using CRM and other relevant corporate systems following established best practices.
  • Establish and adhere to high ethical and performance standards.
  • Perform additional duties as assigned.

Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Minneapolis, Minnesota

Founded

1981

Simplify Jobs

Simplify's Take

What believers are saying

  • Large pharma delivers sixth straight quarter of double-digit organic growth.
  • Spatial Biology grows mid-teens and GMP proteins nearly 50% in Q3 2026.
  • Adjusted operating margins expand 310 basis points to 34.2% via expense management.

What critics are saying

  • Emerging biotech declines high single digits for sixth consecutive quarter.
  • US academic funding cuts cause Protein Sciences revenue to drop 1% to $226.2M.
  • Exosome Diagnostics divestiture to MDxHealth creates permanent 1-2% revenue hole.

What makes Bio-Techne unique

  • Consolidates ten brands into R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.
  • Expands COMET spatial biology with SPYRE Focus Panels and seqLA amplification kits.
  • Provides GMP proteins and proteomic instruments for cell therapy workflows.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bio-Techne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Short-term Disability

Long-term Disability

Pet Insurance

Legal Services

401(k) Company Match

Company Equity

Professional Development Budget

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

Unlimited Paid Time Off

Hybrid Work Options

Employee Stock Purchase Plan

Company News

Yahoo Finance
Mar 26th, 2026
Bio-Techne tops Q4 research tools earnings with $295.9M revenue beat

Bio-Techne reported fourth-quarter revenues of $295.9 million, flat year-on-year but exceeding analysts' expectations by 2%. The life sciences company, which manufactures specialised reagents, instruments and services for research and diagnostic testing, delivered a strong quarter with an impressive beat on organic revenue estimates. Across the research tools and consumables sector, the 10 tracked companies reported satisfactory Q4 results, with revenues beating consensus estimates by 1.2%. However, share prices have struggled, falling an average of 18.6% since the latest earnings results. The subsector faces challenges including high R&D investment requirements, pricing pressures and vulnerability to research funding cycles, though opportunities exist in emerging fields like synthetic biology and laboratory automation.

PR Newswire
Mar 25th, 2026
Bio-Techne expands COMET spatial biology suite with new SPYRE Focus Panels and Amplification Kits

Bio-Techne Corporation has expanded its COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits. The additions include Stroma and Vessel panels, alongside enhanced detection capabilities using sequential and enhanced layered amplification (seqLA) technology for low-abundance targets. The modular antibody panels feature validated antibodies with ready-to-use protocols, allowing researchers to reduce optimisation time whilst maintaining flexibility to incorporate their own markers. Updated HORIZON Image Analysis Software supports the new tools, streamlining tissue analysis workflows. The enhancements strengthen Bio-Techne's integrated spatial biology ecosystem for research and preclinical therapeutic development. Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.

Bio-Techne
Mar 25th, 2026
Bio-Techne advances Spatial Biology with modular expansion of COMET(TM) Suite.

Bio-Techne advances Spatial Biology with modular expansion of COMET(TM) Suite. March 25, 2026 * New SPYRE(TM) Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. * SPYRE(TM) Amplification Kits leverage sequential and enhanced layered amplification (seqLA(TM) technology enabling improved detection of low-abundance and challenging targets. * Enhancements strengthen the fully integrated COMET spatial biology ecosystem, supporting increased consumables adoption and panel expansion. MINNEAPOLIS, March 25, 2026 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the expansion of its COMET(TM) solution portfolio with the addition of the new SPYRE(TM) Focus Panels and SPYRE(TM) Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON(TM) Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. "Researchers need tools that make it easier to extract meaningful answers from complex tissue samples," said Steve Crouse, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "Innovation is one of Bio-Techne's key differentiators, and SPYRE Focus Panels and SPYRE Amplification Kits reflect that strength. By incorporating these capabilities into the COMET Suite, we are giving researchers a more flexible, faster, and higher sensitivity workflow that enables researchers to achieve deeper insights with greater confidence." SPYRE(TM) Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE(TM) Amplification Kits use seqLA(TM) technology to improve the detection of low-abundance and difficult-to-detect targets. "Utilizing the pre-optimized SPYRE panel has not only increased the capacity of conventional multiplex immunofluorescence but also enabled a one-day experimental protocol," said Prof. Joanne Edwards, Professor of Translational Cancer Pathology, University of Glasgow. "The COMET workflow is straightforward and flexible, allowing us to easily integrate our own antibodies of interest. This technology provides insightful data, facilitating the simultaneous investigation of tumor and microenvironment cells within the same sample." Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample. ABOUT BIO-TECHNE: Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information, visit www.bio-techne.com or follow the Company on social media at LinkedIn, X and YouTube. MEDIA CONTACTS: David Clair, Vice President Investor Relations [email protected] SOURCE Bio-Techne Corporation Released March 25, 2026

Yahoo Finance
Mar 11th, 2026
Bio-Techne added to Madison Mid Cap Fund amid research spending concerns

Bio-Techne Corporation, a life sciences research leader, was added to Madison Mid Cap Fund's portfolio in the fourth quarter of 2025, according to the fund's investor letter. The company manufactures and sells life science reagents, instruments and services, including over 6,000 proteins, 400,000 antibody types and 2,400 diagnostic assays. Madison Mid Cap Fund cited Bio-Techne's recurring revenue model, which comprises approximately 80% of its business, and expressed optimism about the new CEO's strategy to expand the company's leadership position in protein research. The fund purchased shares at what it considers a discount due to concerns about customer research spending. Bio-Techne reported $295.9 million in revenue for the second quarter of fiscal 2026, unchanged from the previous quarter. The company currently has a market capitalisation of $8.26 billion.

Pathology In Practice
Feb 17th, 2026
Bio-Techne's Ella platform gains CE-IVD marking

Bio-Techne's Ella platform gains CE-IVD marking. * February 17, 2026 Bio-Techne has announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. "Ella's CE-IVD certification marks a significant step forward in advancing precision diagnostics," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It reflects our commitment to providing innovative tools that enhance clinical decision-making and improve patient outcomes." With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organisations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.